APC News
Published January 1, 2023
APC member TW Taylor with Williamsburg Drug in Williamsburg, VA, has been using Outcome MD for nearly nine months, and he reports that, so far, the platform has been an excellent resource for his compounding pharmacy.
Published January 1, 2023
This week we debut “What We’re Working on Right Now,” the first in what will be an ongoing series of short videos (under 4 minutes!) designed to keep our members in the know on APC’s advocacy activities.
Published January 1, 2023
APC’S Owner Summit 2023 is the year's premier in-person learning, planning, and idea-sharing event for compounding pharmacy owners and managers.
Published January 1, 2023
APC recently submitted a comment letter on DTE to the FDA docket outlining our concerns with the recent reclassification of DTE.
Published January 1, 2023
EduCon is the conference for keeping your team members current and compliant, and it’s coming up February 9-10, 2023. Best of all, you can earn up to 12 CE hours.
Published January 1, 2023
APC has notified USP that it will appeal certain provisions of the revised USP Chapter <797> and has requested 30 days to file the substance of that appeal.
Published January 1, 2023
We launched our new "company" membership category in March 2022. As a result, we've grown from about 900 individual members last March to nearly 4,000 total members today—and we're still growing.
Published January 1, 2023
We’re deeply grateful to all who made investments in APC in 2022
Published December 12, 2022
APC members recently approved bylaws amendments to eliminate the office of president and change the way Alliance officers are elected.
Published December 12, 2022
APC recently submitted a comment letter to FDA following the agency's communications to NABP stating that Thyroid USP was a biologic and therefore ineligible for compounding.
« Newer Entries • Older Entries »